Understanding IMDC Criteria for Metastatic RCC (Heng criteria)

**Step 1**
**Before treatment**

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Threshold</th>
<th>Yes (1) / No (0)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time from initial diagnosis to treatment</td>
<td>&lt; 1 Year</td>
<td>1 / 0</td>
</tr>
<tr>
<td>Karnofsky Performance Score (KPS)</td>
<td>&lt; 80%</td>
<td>1 / 0</td>
</tr>
<tr>
<td>Low Hemoglobin</td>
<td>&lt; LLN</td>
<td>1 / 0</td>
</tr>
<tr>
<td>High Calcium</td>
<td>&gt; 10mg/dL</td>
<td>1 / 0</td>
</tr>
<tr>
<td>High Platelet</td>
<td>&gt; ULN</td>
<td>1 / 0</td>
</tr>
<tr>
<td>High Neutrophil</td>
<td>&gt; ULN</td>
<td>1 / 0</td>
</tr>
</tbody>
</table>

**Total**

**Step 2**
**Risk Categories**

- Favourable Risk: 0
- Intermediate Risk: 1 - 2
- Poor Risk: ≥ 3

**Step 3**
**Treatment Selection**

About IMDC Risk Categories
75 – 80% of patients selecting 1st line mRCC treatment options have at least 1 of these risk factors, therefore classifying their mRCC as intermediate/poor risk. Risk classification may change over time and may help in selecting treatments such as immunotherapy.

Legend:
- KPS = Karnofsky Performance Score
- LLN = Lower Limit of Normal
- ULN = Upper Limit of Normal
- IMDC = International Metastatic Renal Cell Carcinoma Database
- © IKCC = International Kidney Cancer Coalition, www.ikcc.org
- Search for us on Facebook as: ikcc
- Follow us on Twitter: @IKCTrials
- @IKCCorg